Rhodes Melissa 4

What Happened

• Melissa Rhodes, Chief Operating Officer of Avalyn Pharma (AVLN), was granted a derivative equity award on 2026-04-29. The Form 4 reports an award for 211,975 shares at an acquisition price of $0.00 (derivative instrument), filed on 2026-05-01. This is a grant/award (not an open‑market purchase or sale).

Key Details

• Transaction date: 2026-04-29; Form 4 filed: 2026-05-01 (timely filing).
• Transaction type/code: A — Grant, award or other acquisition (derivative).
• Shares/units reported: 211,975 shares; reported acquisition price: $0.00.
• Vesting: 25% vests and becomes exercisable on September 12, 2025; remaining 75% vests in 36 equal monthly installments thereafter, subject to continued service (per footnote).
• Shares owned after transaction: not specified in the provided filing details.
• No indication of an immediate sale or cash exercise in this filing.

Context

• This filing documents an equity award (options or similar derivative) that vests over time; the recipient has not sold shares and did not pay cash at grant. Such awards are common as executive compensation and do not by themselves indicate immediate market activity. When options become exercisable in the future, exercising or selling would be reported in subsequent filings.